Transseptal guide wire puncture system

Information

  • Patent Grant
  • 11878131
  • Patent Number
    11,878,131
  • Date Filed
    Tuesday, November 30, 2021
    2 years ago
  • Date Issued
    Tuesday, January 23, 2024
    3 months ago
Abstract
A trans-atrial septal catheter system for delivery of a steerable sheath into the left atrium contains three components. The first component is a three-segmented needle-guide wire composed of a distal needle designed to flex sharply in relation to the conjoined looped guide wire segment after fossa ovalis puncture and needle advancement. The distal guide wire loops are advanced into the left atrium maintaining the angled needle in a central location relevant to the loops for preserving an atraumatic position while stabilizing the loops in the left atrium. The elongated proximal extra stiff guide wire segment is conjoined to the looped segment which crosses the fossa ovalis and extends proximally to become externalized to the femoral vein. This segment is extra stiff and significantly elongated to permit catheter and device exchanges. The guide wire serves as a support rail over which the dilator and sheath can be advanced into the left atrium. This transseptal system is uniquely forward looking and permits cautious and iterative delivery of the dilator into the fossa ovalis for “tenting” by way of a proximal sheath activator that interacts with the dilator. The proximal externalized GW is then advanced to permit puncture of the fossa ovalis. After puncturing a precise location of the fossa ovalis, the needle and coiled guide wire loops are further advanced into the left atrium. With the proximal activator, the dilator is advanced across the fossa ovalis into the left atrium using single-handed maneuvering for separate dilator advancement and steering of the sheath by way of turning or actuating the sheath handle.
Description
FIELD OF THE INVENTION

The present invention is directed to a system for performing intracardiac transseptal puncture and guide wire access to left heart structures. More specifically, the present invention is directed to achieving transseptal puncture in a highly efficient and safe manner both to gain access to the left atrium by way of a distal needle segment, and mid-looped or coiled left-atrial segment and linear elongated proximal segments. It serves as a platform for structural or other device delivery to the left atrium in the heart. A uniquely configured steerable sheath and dilator may be incorporated with this needle-guide wire. Alternatively, it can be used with most commercially available dilator-sheath transseptal catheter systems.


BACKGROUND

Transseptal punctures are generally used to access the left atrium (LA) of the heart by way of the right atrium (RA). Access to the LA is commonly required for atrial fibrillation ablation and, more recently, treatment of valvular and other structural heart diseases. The current transseptal device(s) must be able to locate specific locations on the fossa ovalis (“FO”) reliably to safely and accurately puncture the FO septum for a given procedure. Inadvertently, puncturing structures such as the aorta, left or right atrial free wall or pulmonary vein can result in cardiac perforation and tamponade. In addition, highly specific sites on the FO must now be traversed to pinpoint specific left heart targets for device positioning.


Current transseptal procedures have specific challenges, including: (1) difficulty engaging with precision and stability on specific locations of the FO resulting from, for example, severe kyphosis, altered cardiac orientation in relation to external landmarks, abnormal cardiac rotation (secondary to multiple cardiac pathologies) and highly variable FO positions and configurations on the intra-atrial septum; (2) difficulty with needle advancement, often due to thickened or scarred septum; (3) redundant or aneurysmal septum leaving the apex of the tented needle on the FO, adjacent to the LA free wall and thus at risk for perforation and pericardial tamponade; and (4) prior septal occluder placement necessitating alternative puncture locations on the native septum or direct occluder puncture.


Abbreviations

Unless otherwise noted, the following abbreviations apply throughout the disclosure:

    • FO: fossa ovalis 202
    • Fr: French (increments for catheter sizing diameter)
    • GW: guide wire 10
    • LA: left atrium 208
    • LAA: left atrial appendage 210
    • MRI: magnetic resonance imaging
    • MV: mitral valve 212
    • RA right atrium 206
    • TEE: transesophageal echocardiography
    • TTE: transthoracic echocardiography


SUMMARY OF THE DISCLOSURE

The present invention relates to a unique catheter system and more specifically a novel needle-guide wire 10 for use in atrial transseptal puncture with a uniquely configured needle 12 distally in continued proximity with the segmented GW 10 for catheter system device delivery. The general target for puncturing the atrial septum in the heart 200 is the FO 202, a depression on the right side of the intra-atrial septum 204 on the wall between the right atrium 206 and left atrium 208. The FO 202 is the remnant of a thin fibrous membrane that usually covers the foramen ovale during fetal development.


Specifically, the present invention is directed in part to a transseptal GW 10 incorporated with a transseptal needle 12. The GW 10 segment comprises a stiff proximal segment end 16 and a middle loop segment 14, wherein the distal end 22 comprises the junction of the transseptal needle 12. At least two mid-segment GW loops 24, 26 come to rest in the LA 208. The middle loop segment 14 is formed of a shape memory material to form at least two looped segments, the second more distal, usually outer, broad coil 24 and a first, more proximal, or inner coil 26; wherein the middle segment 14 is in continuity with the elongated linear extra-stiff GW segment 16 at proximal end 25, which eventually rests externally for exchanges.


The present invention is further directed to a transseptal GW puncture system that traverses the FO 202, comprising a proximal end 16, a distal end 22, a middle coiled segment 14, a transseptal dilator 108, and a sheath 100. The distal end of the GW puncture needle 18 comprises a transseptal needle 12 attached to the looped GW segment 14 at its distal end 22 and in turn is positioned in continuity with the distal end 17 of the linear, extra-stiff GW segment 16. The transseptal needle 12 has shape memory at the point of attachment to the looped GW segment 14 wherein the shape memory is sufficient to have the transseptal needle 12 retain a pre-specified abrupt angle with respect to the looped guide wire segment 14 to maintain atraumatic stability within and central to the loops 24, 26. One or more of the loops 24, 26 are positioned and stabilized in the LA 208 resting adjacent to the inner surface of the LA 208. The middle looped segment 14 is formed of a shape memory material to form the two loops 24, 26; wherein the proximal end 25 of the more proximal coil 24 is in continuity with the proximal elongated extra-stiff segment of the GW 16; and wherein a secondary bend 29 is positioned in the RA 206 transitioning into the elongated, linear proximal most segment of the GW 10.


The transseptal dilator 108 comprises an elongated catheter 109 which rests within the sheath 100, tapering down to a narrowed dilator distal segment 110, wherein the catheter lumen 111 throughout remains compatible with the GW 10, which may have a full spectrum of diameters ranging from 0.021 inches to 0.035 inches or more. At some point along the distal segment 106 is a radiopaque marker 122 positioned to be overlapped with the radiopaque tip marker 123 on the sheath 100 when at that point the transseptal dilator 108 and sheath 100 are of equivalent external diameters. The dilator 108 is advanced forward into a precise position of the FO 202 for “tenting” the FO 202 by way of a series of forward movements of the actuator 112 adjacent to the distal end of the handle 104. Steerable maneuvers on the proximal sheath handle 104 permit antigrade and retrograde flexion, and torqueing anterior or posterior of the entire sheath 100 will be carried out to position the distal end 124 of the sheath and the retained dilator tip 110 adjacent to the specific FO site for the specific procedure. Advancement and retraction movements of the dilator distal segment 110 relative to a stabilized sheath 100 with the use of an actuator 112 on the proximal sheath 100 interacts with the proximal end 119 of the dilator 108.


Once the FO 202 is tented with the dilator 108 which contains the transseptal needle 12, the needle 12 is advanced, puncturing the FO septum 202 and crossing into the LA 208. The transseptal needle 12 folds or bends from shape memory at a discrete angle at the proximal end/hinge point 20 on the coiled GW segment 14 to which it is connected after being advanced across the FO 202. It forms an angle which may range from about 45° to 140°. Further advancement of the transseptal GW 10 will position the looped section 14 coils of the GW 10 stable within the LA chamber 208 aiding also in preserving the needle position atraumatically in the central LA 208 by way of remaining central to the loops. Preferably, the GW coils 24, 26 have a small inner diameter coil 26 and larger outer diameter coil 24 aiding in preserving the needle 12 highly central to the LA 208. The smaller in diameter inner coils prevent excessive needle 12 damage to the tissue in the LA wall. In another embodiment, the coils 24, 26 may be of equal diameters.


In another embodiment, the coils 24, 26 may be offset, as illustrated in FIGS. 3 and 4, to further aid in preserving a central location of the needle 12 which can also be folded in a third dimension, an additional feature making it less susceptible to perforating LA 208 structures when the folded distal transseptal needle 12 is advanced and deflected medially further aiding in maintaining a central needle 12 position within the offset but equal spaced loops 14. Coils 24, 26 may be offset by approximately 0.75-2 cm. The coils 24, 26 are intermediate in stiffness allowing for less traumatic interaction with the LA free walls. A secondary bend 29 in the right atrial GW segment aids in preserving a perpendicular trajectory across the FO 202 and co-axially in the IVC 215. The elongated, proximal extra-stiff GW segment 16 will have a preferable length of 260 cm (but may be significantly longer) for purposes of catheter or device exchange.


Novel features unique to this dilator and deflectable sheath in the system include a longer extendable dilator tip in relation to the sheath. Strategic positioning by overlapping the dilator radiopaque marker 122 and sheath radiopaque marker 123 for alignment at equivalent external diameters permit smooth transitioning of the transseptal dilator 108 and sheath 100 across the membrane of FO 202.


The forward positioning of the catheter system of the present invention allows for precise positioning of the distal sheath for precise device positioning thereby establishing ideal LA 208 positioning ultimately dictated by the specific left heart target for a given device, i.e., LAA 210, MV 212. The system is intuitive and simple to accurately position on a specific FO 202 target by using iterative dilator advancement under echo or other imagining guidance. After the coils have been advanced across the FO 202 and secured in the LA 208, the dilator 108 is then advanced over the coiled GW 10 into the LA 208 preserving the overlapping radiopaque segments in place until the sheath 100 has crossed into the LA 208. Overlapping radiopaque markers 122, 123 on the distal dilator end 106 and sheath tip 124 are used to confirm that they are at equivalent diameters for smooth simultaneous advancement of the dilator 108 and sheath 100 across the FO 202.


The deflectable and steerable nature of the sheath 100 will permit the sheath 100 to obtain the directionality, angulation and reach using a single size forward looking catheter system for the variety of RA 206 sizes and FO 202 angles in various patient-specific anatomy.


The collective system preferably includes a needled GW wire 10 delivered by the “one size fits all” catheter system for iteratively advancing the dilator 108, containing the retracted needle 12, into a precise tenting position on the FO 202. An actuator 112 on the sheath 100 adjacent to the handle 104 permits highly controlled advancement of the distal segment 110 for “tenting” the FO membrane prior to needle puncture. The actuator 112 can be advanced or retracted with the operator's thumb without removing the operator's hand from the rotatable handle 104. The dilator 108 may have a more flexible distal segment to permit smooth tracking over the coiled GW segment in the LA 208. The deflectable sheath tip 124 may have monopolar or bipolar directionality. Preferably the steerable sheath 100 will have a distal fixed 2° bend within the RA 206 which may range from 2° to 20° to more easily establish perpendicularity to the FO 202. Standard, commercially available sheath dilator catheters may also be used in combination with the previously described novel needle GW.


Advantageously, the device satisfies the following: (1) improved ease of use; (2) intuitive manipulation for precise distal control; (3) improved device and procedural efficacy; (4) increased device safety across a wide range of operator skills; (5) enhanced workflow and decreased procedural times; and (6) decreased procedural costs secondary to a combined needle GW.


The objects and advantages of the invention will be highlighted in greater detail in the following description of the preferred embodiment of the invention in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

In order that the invention may be readily understood, embodiments of the invention are illustrated by way of examples in the accompanying drawings, in which:



FIG. 1 is a side plan view of the first embodiment of the present invention of the combined transseptal needle and GW profiled in the frontal plane.



FIG. 2 is a side plan view of a second embodiment of the combined transseptal needle and GW of the present invention in the frontal plane.



FIG. 3 is a side plan view of a third embodiment of the present invention of the combined transseptal needle and GW with offset loops viewed from a frontal planar perspective.



FIG. 4 is a front plan view of the transseptal needle of FIG. 3 which has been rotated ninety degrees.



FIG. 5 is a side plan view illustrating a representative unipolar deflectable sheath for use with the needle-GW in the present invention.



FIG. 6 is a side plan view illustrating a dilator for use with the deflectable sheath of FIG. 5.



FIG. 7 is a front view schematic representation of the human central venous circulatory system including the heart and venous system with a steerable sheath present in the system.



FIG. 8 is a front view schematic representation of a cross-section of the human heart with the deflectable sheath positioned across the atrial septum and positioned in the LA with the distal needle GW loops in the LA.





DETAILED DESCRIPTION

With reference to the guide number in the drawings, the transseptal puncture system of the present invention is preferably a “one size fits all” system whereby a single-sized system may be used in a variety of anatomical configurations and atrial sizes. An exception to this new standard is directed to the use of multiple wire diameters on the order of about 0.021 inches to greater that 0.035 inches. The system includes specialized components, including an exchange GW with a distal transseptal needle and adjacent coils or loops for GW securement in the LA 206. In addition, the catheter components may include a novel dilator which interacts with an actuator on the proximal sheath handle for controlled positioning on the FO aided by the steerable sheath.


The Needle-Guide Wire


Reference is made to FIGS. 1-4 illustrating a needle-guide wire 10. The transseptal needle-GW 10 should be a single component and avoid the need for a separate transseptal needle, multiple exchanges and multiple lengths and curves for various anatomies. The single wire has at least three defined segments: (1) the distal transseptal needle 12; (2) the middle or looped LA segment 14; and (3) the proximal elongated linear, extra-stiff GW segment 16.


Transseptal Needle 12


The transseptal needle 12 is positioned in continuity with the distal end 22 of the GW loop segment 14. The transseptal needle 12 is preferably relatively short, with a length between about 0.75 to about 2.0 cm. The needle 12 also should preferably have an ultra-low profile tip 18. The proximal end 20 of the needle 12 in continuity with the adjacent distal loop segment 14 is linear when retained in the central lumen 111 of the dilator tip prior to advancement.


The transseptal needle 12 has a lubricious coating to minimize resistance and a sharply tapered tip 18 to puncture and easily transition across the FO 202 (illustrated in FIG. 8) including those that may be densely scarred or aneurysmal. Inadvertent needle lurching across the FO membrane and loss of the preferred puncture site is avoided by the extra-fine point on the needle tip 18, slow iterative delivery of the forward-looking tapered transseptal dilator 108 into the FO 202 for stable positioning and “tenting” of the membrane by the dilator tip 18 which is in turn supported by a steerable transseptal sheath 100. With this forward looking system, unintended anterior or posterior, torqueing forces resulting in sliding across the FO 202 should be greatly minimized.


The transseptal needle 12 is preferably composed of a metallic material, such as stainless steel or alloy including nitinol with shape memory, and is attached to the GW loop segment 14 for example with a weld or possibly interdigitating slots which interact to form a more stable, yet flexible, union allowing the needle to fold on itself thereby avoiding puncturing the LA free wall, the pulmonary vein, etc. Other means of creating a pre-shaped angle between the needle 12 and loop segment 14 can also be conceived and utilized.


The transseptal needle 12 sharply angles at the proximal end/hinge point 20 where it connects to the distal end 22 of the looped GW segment 14 having retained a pre-specified angle central to the LA loop segment 14, thus maintaining atraumatic stability within the central LA loop segment 14, thus preventing contact and possible perforation of LA 208 structures including a pulmonary vein, LA free wall and LAA 210.


Following the wire advancement and transseptal puncture, the needle 12 abruptly flexes centrally preferably at an acute angle with the adjoined looped GW segment 14 as illustrated in FIGS. 1-4. The needle 12 remains linear after entering the LA 208 but flexes inward, preferably at an angle of about 45° to 140° relative to the distal looped GW segment 14. The diameter of the transseptal needle tip 18 can be ground down to an ultra-low profile and tapered back to conjoin the distal loop segment 14, most likely transitioning to a profile in the range of 0.021″ to 0.035″ or greater.


Guide Wire Loop Segment 14


The looped GW segment 14 is designed to stabilize the GW 10 position atraumatically in the LA 208 and, in addition, assists in protecting the left atrial free wall from unwanted needle puncture. Two or more looped segments 24, 26 may typically range between about 2.5 cm and 4.0 cm in diameter and formed by shape memory as it exits from the transseptal dilator 108 into the LA 208. The distal GW looped segment 14 in one embodiment would be formed by two roughly equal in size circular or possibly non-circular loops potentially in a plurality of shapes which are again formed upon deployment in the LA chamber, as illustrated in FIGS. 3-4.


The coils provide at least four useful functions:

    • 1. The coils can confirm the correct LA chamber positioning, by taking on the unconstrained, known shape within the LA 208.
    • 2. The coils 14 maintain stable positioning in the LA 208 to avoid inadvertent withdrawal of the GW 10 into the RA 206 or forceful needle tip 12 advancement into the LA free wall or pulmonary vein.
    • 3. The outer broad coil 24 provides a longer GW support ramp over which the dilator 108 and sheath 100 can be advanced with less resistance into the LA 208 around the curve to facilitate catheter support.
    • 4. The coils form an outer protective shield in which the centrally positioned needle 12 is kept at a safe distance from penetrating LA 208 structures.


In another embodiment, there are at least two circular coils, the inner coil 26 diameter being smaller than the outer coil 24 diameter, as illustrated in FIGS. 1-4, the inner coil thus central to the outer coil 24. In this embodiment, the larger, outer coil 24 can be compressed by LA 208 structures in the absence of any conformational change of the inner coil 26 thus further protecting deformity of the distal needle 12 and preserving its central location.


As an example, the inner coil 26 of the GW 10 may have a diameter between about 1.5 cm and 3.0 cm, preferably about 2.5 cm. The outer coil 24 may have a diameter between about 3.0 cm and 4.0 cm, preferably about 3.5 cm.


In a third embodiment, the two coils 24, 26 have parallel portions 24a and 26a and are unequal in diameter, but can be offset by about 0.75 cm to about 2.0 cm, which in combination with a second preformed bend at the junction of the distal transseptal needle 12 and the GW loop segment 14 in the third dimension central to the two offset wire coils 24, 26, as illustrated in FIG. 4. Its purpose is to further aid in preventing needle perforation of the LA 208 by allowing the needle 12 to not only be centered circumferentially in two dimensions upon flexion with this embodiment but the needle 12 is to be directed centrally in a third dimension between the breadth of two offset loops 24, 26. The distance between the parallel portions 24a and 26a of coils 24, 26, as illustrated by dotted line 25a, would preferably be about 1 cm, and may range from about 0.75 cm to about 2.0 cm.


Proximal Guide Wire Segment 16


The proximal GW segment 16 is in continuity with the adjacent coil segment 14 at the distal end 17 of the segment 16. The proximal GW segment 16 includes a proximal free end 28, which is exteriorized with adequate length to permit catheter or device exchange while preserving distal GW loop segment 14 positioned in the LA. The distal end 17 of this segment transitions linearly across the atrial septum into the LA 208. There is then preferably a shallow fixed second degree bend 29 roughly in the mid-RA 206, retaining a preferable angle of 2° to 20°. The elongated proximal extra-stiff GW segment 16 extends from most distal end of the long proximal segment 17 to the most proximal end 28 having a preferred diameter of 0.021″ to 0.035″. The long proximal extra stiff GW segment 16 may extend from 240 cm to 300 cm, preferably 260 cm in length. This long, extra stiff GW segment 16 will serve as a supportive rail for exchanging an array of catheters and devices for delivery to left heart targets.


Guide Wire Introduction Sheath 100


Referring to FIG. 5, the transseptal delivery sheath (or sheath) 100 is preferably a unipolar, but may be a bipolar, deflectable sheath actuated with a rotatable proximal ergonomic handle 104 for superior/inferior flexion, and one-to-one sheath torque control for optimal anterior/posterior positioning, advancement or retracting the transseptal sheath 100 permits superior and inferior positioning for controlled, atraumatic guidance in all planes. The sheath 100 has a proximal end 102 located adjacent the actuator 112 and a distal segment 107. Current transseptal systems designed for commercial use are brought into the FO 202 using a clockwise torque of the sheath/dilator system generally from a femoral vein access sight that may be overly aggressive (excessive in length) which may in turn result in inadvertent “stored up” torque if the over-reaching dilator 108 momentarily “catches” distally on an atrial septum prominent ridge. Further efforts to position the dilator distal segment 110 within the FO 202 may result in perforation of the RA 206 free wall or appendage. Conversely, a dilator 108 of insufficient length or “reach” and inability to engage the membrane across the FO 202 results in an inability to puncture the FO 202.


Multiple sheath sizes for each system must be available to accommodate variable RA sizes and configurations in these current commercially available systems. The sheath 100 has an ergonomic two-way rotatable handle 104 for superior and inferior distal sheath flexion, illustrated by arrow 125 and reach at the sheath tip 124 of the sheath 100. In addition, 1:1 torque transfer distally in an anterior to posterior position is accomplished through wire braid reinforcement (not illustrated) of the sheath 100 which also improves back up support for enhanced device delivery. The sheath 100 is initially positioned adjacent to but without engagement of the atrial septum using fluoroscopic and TEE guidance and when available, possibly real time MRI and computer tomography.


As will be illustrated shortly, once the sheath 100 is accurately positioned at the appropriate short distance from the FO 202 (probably about 0.5 to about 2.0 cm) in the RA 206 under imaging guidance, the dilator 108 is advanced while keeping the sheath 100 stationary. The sheath handle 104 and adjacent actuator 112 for the dilator will permit total system (sheath and dilator) manipulation with one hand kept in position without need for use of the operator's contralateral hand. The actuator 112 for the dilator 108 can be manipulated by the operator's thumb or other digit for iterative forward advancement or retraction by interacting with the frictional elements 121 on the dilator 108. The wire-braid, reinforced sheath 100 provides strong backup, kink-resistant support for advancing the dilator distal segment 110 of the dilator 108 and subsequently the dilator 108 into a precisely controlled specific location of the FO 202 for “tenting” of the membrane.


The sheath 100 preferably includes but will not necessitate a dilatable shaft to accommodate highly variable device profiles; on the other hand, a series of fixed diameter sheaths may be used to accommodate a variety of device profiles. Ideally expandable or dilatable sheaths, ranging from about 8.5 Fr to potentially up to 30 Fr, could eliminate the need for keeping multiple sheath diameters available for different procedures. One embodiment is thus a single sheath size which is conformed to be dilatable across a range of diameters. Transseptal sheaths which may require deflectability at two or more distances from the proximal handle may be preferred for device delivery around complex or multiple curves.


A plurality of other supportive structures may run linearly within the sheath body to preserve an adequate level of support for subsequent device delivery across more angulated anatomy. A 2° to 20° secondary bend may be positioned proximal to the more distal deflectable bend which would aid in achieving a more perpendicular angle at the FO for strong coaxial backup support. In addition, this would permit distal flexion greater than 180°, which may on occasion be needed to achieve appropriate sheath positioning within the medial aspects of the left heart. A tight hemostatic valve on the sheath hub 114 would minimize back bleeding around the GW 10, including those with diameters down to 0.021 inch. Preferably, the sheath 100 will be 90 cm long (70 cm usable length) or longer. Hubs for locking the dilator to the sheath may be incorporated.


Transseptal Dilator 108


The transseptal dilator 108 (or “dilator”) preferably has an ultra-low-profile distal segment 110 with a reverse taper back, illustrated at 106, to a fixed external diameter 118 at the distal end 106 of the dilator 108, compatible with the internal sheath diameter. The dilator 108 can be advanced in a forward motion until “tenting” of the FO membrane is demonstrated in a precise position specific to the position visualized by TEE or other real time imaging detectors specific to the procedure being performed.


In a preferred embodiment, the dilator 108 will interact with the actuator 112 adjacent to the sheath handle 104 by way of a frictional contact element 121 or use of interlocking gears for precise gentle control of the dilator movements. An actuator 112 that permits advancement or retraction of the dilator will preferably be controlled with the ipsilateral thumb, preserving the ability to maneuver both the dilator 108 and sheath handle 104 with one hand. The dilator 108 has variable flexibility along its length, with a more flexible distal segment 118 to prevent excessive straightening or movement of the catheter system as it is advanced over the GW looped segment 14.


The maximum length of the dilator distal segment 106 should be able to be advanced beyond the stationary distal sheath 100, preferably up to about 5 cm, although it may be altered to extend beyond the sheath tip from about 3.0 cm up to about 8.0 cm. This allows controlled advancement of the dilator 108 across the FO 202 and into the LA 208 over the distal GW 10. After the septal puncture and advancement of the dilator 108 into the LA 208, while maintaining the sheath 104 fixed in the RA 206, there should be ample space until the radiopaque markers 122, 123 overlap in the RA 206 side of the septum following which the composite system with transseptal dilator 108 and sheath 100, having flush external diameters, are now able to be advanced into the LA 208 as a single unit.


The dilator distal segment 106 ends in a low profile tip 110 and has a radiopaque marker 122 proximal to the dilator distal segment 106 matching the profile of the radiopaque marker 123 on the sheath tip 124 rendering a point of smooth transition between the two for simultaneous advancement across the FO 202 preventing “hang-up” of the sheath tip edge on the atrial septal crossing point.


Method of Operation


Referring to FIGS. 7 and 8, an exemplary method of operation is as follows on a human patient 201. As described below, this technique generally is guided by TEE or TTE supplemented with standard fluoroscopy. It should be understood that the procedure could also be guided by intra-cardiac echo, real-time MRI or image integration with pre-procedural volume rendered computer tomography images. This later imaging method uses standard fluoroscopic images to which the pre-acquired computer tomography images may be oriented and superimposed on for guidance. Reference is made to U.S. Pat. No. 8,900,214 to Nance et al, which is incorporated herein for a general description of human anatomy, including the heart 200, and insertion of a transseptal sheath 100 into the atrial region.


A 0.032 J-tipped GW is advanced from the right femoral vein 216 into the superior vena cava 218 using fluoroscopy. The steerable sheath 100 and dilator 108 are advanced as a unit over the J-tipped GW 10 and positioned in the mid RA 206. The J-tipped GW 10 is removed and the dilator 108 is flushed. The distal tip 18 of the GW 10 is then advanced into the 0.032 compatible dilator 108 under fluoroscopy and the distal tip 18 of the GW 10 positioned just proximal to the dilator distal segment 110.


The ergonometric handle 104 on the sheath 100 is oriented axially to permit the deflectable tip 124 to be ante-flexed toward the FO 202. One to 3 cm of the dilator 108 is advanced distal to the fixed sheath 100 fluoroscopically and echocardiographically prior to maneuvering the sheath 100 toward the FO 202. To accomplish this anterior or posterior orientation, the sheath 100 is torqued anteriorly or posteriorly. The sheath 100 is advanced or withdrawn to gain a more superior or inferior position. Once again, the proximal sheath handle 104 is turned to flex the distal tip 124 to a superior, i.e., retrograde, or inferior, i.e., antigrade, trajectory. A TEE probe is most commonly used for optimal imaging of the FO 202 and adjacent dilator distal tip 110 using orthogonal views: bicaval view for superior-inferior orientation and short axis view at the aortic level to demonstrate anterior-posterior positioning. Using these TEE views, a precise position on the FO 202 for a procedure specific puncture can be obtained. The actuator 112 adjacent to the sheath handle 104 is used to slowly and iteratively advance the dilator tip 110 creating “tenting” within the FO 202 and the correct position confirmed by TEE. If the dilator distal tip 110 is incorrectly positioned, the dilator 108 can be withdrawn with the actuator 112 and redirected after manipulating the sheath 100.


With correct positioning confirmed using the tenting position, the GW 10 proximal end and the needle tip 18 punctures and crosses the FO 202 membrane. As the GW 10 is further advanced, the needle 12 flexes sharply at the hinge point 20 where it is attached to the loop segment 14 of the GW 10. As the GW 10 is still further advanced, its distal coils 14 are self-positioned in the LA 208 and the needle 12 kept flexed central to the coils 24, 26. Catheters are always aspirated and flushed with exchanges. The patient is therapeutically heparinized as soon as the GW loop segment 14 is advanced into the LA. Correct positioning of the GW 10 is confirmed by verifying its preformed shape. The coiled or looped segment 14 can take on several different embodiments as noted under the device description. The dilator 108 is advanced over the coiled wire maintaining the sheath 100 in a fixed position within the RA 206.


With the appropriate length of dilator 108 advanced under fluoroscopy, the radiopaque markers 122, 123 on the dilator 108 and sheath tip 124 come to overlap in the RA 206 confirming that the outer diameters of both catheters are equivalent and ready to be advanced into the LA 208 as a single unit. The sheath tip 124 now comes to rest across the FO 202 and in the LA 208. Again, all the dilator 108 and sheath 100 manipulations are carried out as a single-handed procedure. The dilator 108 is removed, keeping the GW wire loops 24, 26 and sheath 100 stationary in the LA 208.


The elongated proximal segment of the GW 10 is loaded with the primary device that is now advanced to the sheath tip 124 and the GW 10 is removed. The sheath 100 can then be more finely manipulated to deliver the device to the target and subsequently deployed. After deployment, the steerable sheath 100 is drawn back into the RA 206 and subsequently removed from the patient. The heparin is reversed with protamine and the percutaneous vascular entry is closed.


This transseptal procedure is carried out with a forward-looking catheter system which is iteratively advanced onto a precise position of the FO 202 prior to being punctured. The nature of the catheter system is such that only one device shape will be required to access the LA 208. This is unlike current techniques where catheters are torqued into the FO 202 using a multitude of catheter sizes which may be initially too small and unable to reach the FO 202 or too long placing the patient at risk for slipping off the FO membrane and potentially perforating the RA free wall.


Any version of any component or method step of the invention may be used with any other component or method step of the invention. The elements described herein can be used in any combination whether or not explicitly described.


All combinations of method steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.


As used herein, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise.


Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.


All patents, patent publications, and peer-reviewed publications (i.e., “references”) cited herein are expressly incorporated by reference in their entirety to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.


The devices, methods, compounds and compositions of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations described herein, as well as any additional or optional steps, ingredients, components, or limitations described herein or otherwise useful in the art.


While this invention may be embodied in many forms, what is described in detail herein is a specific preferred embodiment of the invention. The present disclosure is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated. It is to be understood that this invention is not limited to the particular examples, process steps, and materials disclosed herein as such process steps and materials may very somewhat. It is also understood that the terminology used herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited to only the appended claims and equivalents thereof.


The scope of use for this device can be expanded for other, i.e., nontransseptal procedures, both vascular and nonvascular cavitary organ structures.

Claims
  • 1. A transseptal guide wire, comprising a proximal end, a distal end and a middle segment, a. wherein the proximal end is in continuity with the middle segment via a proximal guide wire segment;b. wherein the proximal guide wire segment is stiff and further comprises a distal segment and a proximal segment connected by a secondary bend in achieving a more perpendicular angle at the tissue for coaxial support;c. wherein the distal end comprises a linear transseptal needle configured to flex at a hinge point from a linear puncturing arrangement to an acute angle with respect to a distal end of the middle segment after puncturing tissue; andd. wherein the middle segment is formed of a shape memory material and preformed to include at least two non-circular coils that form an outer protective shield in which the transseptal needle is positioned centrally within the at least two non-circular coils once the middle segment returns to a preformed configuration.
  • 2. The transseptal guide wire of claim 1, wherein the secondary bend has an angle of 2° to 20°.
  • 3. The transseptal guide wire of claim 1, wherein the proximal guide wire segment has a diameter of 0.021 inches to 0.035 inches.
  • 4. The transseptal guide wire of claim 1, wherein the length of the transseptal needle is between about 0.75 cm and 2.0 cm.
  • 5. The transseptal guide wire of claim 1, wherein the transseptal needle has a lubricous coating and a sharply tapered tip.
  • 6. The transseptal guide wire of claim 1, wherein the transseptal needle has shape memory at the point of attachment to the guide wire, and wherein the shape memory is sufficient to have the transseptal needle retain the acute angle with respect to the distal end of the middle segment to maintain central atraumatic stability.
  • 7. The transseptal guide wire of claim 1, wherein the acute angle is between 45° and 90° with respect to the distal end of the middle segment.
  • 8. The transseptal guide wire of claim 1, wherein at least one non-circular coil is between about 2.5 cm and 4.0 cm in length.
  • 9. The transseptal guide wire of claim 1, wherein the at least two non-circular coils including an inner coil and an outer coil with the inner coil central to the outer coil, wherein the inner coil has a length between about 1.5 cm and 3.0 cm, and the outer coil has a length between about 3.0 cm and 4.0 cm.
  • 10. The transseptal guide wire of claim 1, wherein the shape memory material is nitinol.
  • 11. The transseptal guide wire of claim 1, wherein the at least two non-circular coils are parallel with a distance between the coils about 0.75 cm to 2.0 cm.
  • 12. The transseptal guide wire of claim 1, wherein the at least two non-circular coils are about equal in size.
  • 13. The transseptal guide wire of claim 1, wherein the proximal end has a length between about 240 cm to 300 cm.
  • 14. A transseptal guide wire puncture system, comprising: a. the transseptal guide wire of claim 1; andb. a transseptal dilator for placement of the transseptal needle on the fossa ovalis of a subject.
  • 15. The transseptal guide wire puncture system of claim 14, wherein the transseptal dilator has a lumen having a diameter between about 0.021 inches and 0.035 inches.
  • 16. The transseptal guide wire puncture system of claim 14, further comprising a sheath.
  • 17. The transseptal guide wire puncture system of claim 16, wherein the dilator and the sheath each comprises a radiopaque marker for alignment.
  • 18. The transseptal guidewire of claim 1, wherein the at least two non-circular coils are offset; wherein the transseptal needle is positioned between the offset non-circular coils in a third dimension once the middle segment returns to the preformed configuration.
US Referenced Citations (357)
Number Name Date Kind
175254 Oberly Mar 1876 A
827626 Gillet Jul 1906 A
848711 Weaver Apr 1907 A
1072954 Junn Sep 1913 A
1279654 Charlesworth Sep 1918 A
1918094 Geekas Jul 1933 A
1996986 Weinberg Apr 1935 A
2021989 De Master Nov 1935 A
2146636 Lipchow Feb 1939 A
3429574 Williams Feb 1969 A
3448739 Stark et al. Jun 1969 A
3575415 Fulp et al. Apr 1971 A
3595239 Petersen Jul 1971 A
4129129 Amrine Dec 1978 A
4244362 Anderson Jan 1981 A
4401124 Guess et al. Aug 1983 A
4639252 Kelly et al. Jan 1987 A
4641649 Walinsky et al. Feb 1987 A
4669467 Willett et al. Jun 1987 A
4682596 Bales et al. Jul 1987 A
4790311 Ruiz Dec 1988 A
4790809 Kuntz Dec 1988 A
4793350 Mar et al. Dec 1988 A
4807620 Strul et al. Feb 1989 A
4832048 Cohen May 1989 A
4840622 Hardy Jun 1989 A
4863441 Lindsay et al. Sep 1989 A
4884567 Elliott et al. Dec 1989 A
4892104 Ito et al. Jan 1990 A
4896671 Cunningham et al. Jan 1990 A
4928693 Goodin et al. May 1990 A
4936281 Stasz Jun 1990 A
4960410 Pinchuk Oct 1990 A
4977897 Hurwitz Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5006119 Acker et al. Apr 1991 A
5019076 Yamanashi et al. May 1991 A
5047026 Rydell Sep 1991 A
5081997 Bosley et al. Jan 1992 A
5098431 Rydell Mar 1992 A
5112048 Kienle May 1992 A
5154724 Andrews Oct 1992 A
5201756 Horzewski et al. Apr 1993 A
5209741 Spaeth May 1993 A
5211183 Wilson May 1993 A
5221256 Mahurkar Jun 1993 A
5230349 Langberg Jul 1993 A
5281216 Klicek Jan 1994 A
5300068 Rosar et al. Apr 1994 A
5300069 Hunsberger et al. Apr 1994 A
5314418 Takano et al. May 1994 A
5318525 West et al. Jun 1994 A
5327905 Avitall Jul 1994 A
5364393 Auth et al. Nov 1994 A
5372596 Klicek et al. Dec 1994 A
5380304 Parker Jan 1995 A
5397304 Truckai Mar 1995 A
5403338 Milo Apr 1995 A
5423809 Klicek Jun 1995 A
5425382 Golden et al. Jun 1995 A
5476498 Ayers Dec 1995 A
5490859 Mische et al. Feb 1996 A
5497774 Swartz et al. Mar 1996 A
5507751 Goode et al. Apr 1996 A
5509411 Littmann et al. Apr 1996 A
5540681 Strul et al. Jul 1996 A
5545200 West et al. Aug 1996 A
5555618 Winkler Sep 1996 A
5571088 Lennox et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5599347 Hart et al. Feb 1997 A
5605162 Mirzaee et al. Feb 1997 A
5617878 Taheri Apr 1997 A
5622169 Golden et al. Apr 1997 A
5624430 Eton et al. Apr 1997 A
5667488 Lundquist et al. Sep 1997 A
5673695 McGee et al. Oct 1997 A
5674208 Berg et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5720744 Eggleston et al. Feb 1998 A
5741249 Moss et al. Apr 1998 A
5766135 Terwilliger Jun 1998 A
5779688 Imran et al. Jul 1998 A
5810764 Eggers et al. Sep 1998 A
5814028 Swartz et al. Sep 1998 A
5830214 Flom et al. Nov 1998 A
5836875 Webster, Jr. Nov 1998 A
5849011 Jones et al. Dec 1998 A
5851210 Torossian Dec 1998 A
5885227 Finlayson Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5893848 Negus et al. Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5904679 Clayman May 1999 A
5916210 Winston Jun 1999 A
5921957 Killion et al. Jul 1999 A
5931818 Werp et al. Aug 1999 A
5944023 Johnson et al. Aug 1999 A
5951482 Winston et al. Sep 1999 A
5957842 Littmann et al. Sep 1999 A
5964757 Ponzi Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5989276 Houser et al. Nov 1999 A
6007555 Devine Dec 1999 A
6009877 Edwards Jan 2000 A
6013072 Winston et al. Jan 2000 A
6017340 Cassidy et al. Jan 2000 A
6018676 Davis et al. Jan 2000 A
6030380 Auth et al. Feb 2000 A
6032674 Eggers et al. Mar 2000 A
6048349 Winston et al. Apr 2000 A
6053870 Fulton, III Apr 2000 A
6053904 Scribner et al. Apr 2000 A
6056747 Saadat et al. May 2000 A
6063093 Winston et al. May 2000 A
6093185 Ellis et al. Jul 2000 A
6106515 Winston et al. Aug 2000 A
6106520 Laufer et al. Aug 2000 A
6117131 Taylor Sep 2000 A
6142992 Cheng et al. Nov 2000 A
6146380 Racz et al. Nov 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6193676 Winston et al. Feb 2001 B1
6193715 Wrublewski et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217575 Devore et al. Apr 2001 B1
6221061 Engelson et al. Apr 2001 B1
6228076 Winston et al. May 2001 B1
6245054 Fuimaono et al. Jun 2001 B1
6267758 Daw et al. Jul 2001 B1
6283983 Makower et al. Sep 2001 B1
6292678 Hall et al. Sep 2001 B1
6293945 Parins et al. Sep 2001 B1
6296615 Brockway et al. Oct 2001 B1
6296636 Cheng et al. Oct 2001 B1
6302898 Edwards et al. Oct 2001 B1
6304769 Arenson et al. Oct 2001 B1
6315777 Comben Nov 2001 B1
6328699 Eigler et al. Dec 2001 B1
6360128 Kordis et al. Mar 2002 B2
6364877 Goble et al. Apr 2002 B1
6385472 Hall et al. May 2002 B1
6394976 Winston et al. May 2002 B1
6395002 Ellman et al. May 2002 B1
6419674 Bowser et al. Jul 2002 B1
6428551 Hall et al. Aug 2002 B1
6450989 Dubrul et al. Sep 2002 B2
6475214 Moaddeb Nov 2002 B1
6485485 Winston et al. Nov 2002 B1
6508754 Liprie et al. Jan 2003 B1
6524303 Garibaldi Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6554827 Chandrasekaran et al. Apr 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562049 Norlander et al. May 2003 B1
6565562 Shah et al. May 2003 B1
6607529 Jones et al. Aug 2003 B1
6632222 Edwards et al. Oct 2003 B1
6639999 Cookingham et al. Oct 2003 B1
6650923 Lesh et al. Nov 2003 B1
6651672 Roth Nov 2003 B2
6662034 Segner et al. Dec 2003 B2
6663621 Winston et al. Dec 2003 B1
6702811 Stewart et al. Mar 2004 B2
6709444 Makower Mar 2004 B1
6723052 Mills Apr 2004 B2
6733511 Hall et al. May 2004 B2
6740103 Hall et al. May 2004 B2
6752800 Winston et al. Jun 2004 B1
6755816 Ritter et al. Jun 2004 B2
6811544 Schaer Nov 2004 B2
6814733 Schwartz et al. Nov 2004 B2
6820614 Bonutti Nov 2004 B2
6834201 Gillies et al. Dec 2004 B2
6842639 Winston et al. Jan 2005 B1
6852109 Winston et al. Feb 2005 B2
6855143 Davison et al. Feb 2005 B2
6860856 Ward et al. Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6911026 Hall et al. Jun 2005 B1
6951554 Johansen et al. Oct 2005 B2
6951555 Suresh et al. Oct 2005 B1
6955675 Jain Oct 2005 B2
6970732 Winston et al. Nov 2005 B2
6980843 Eng et al. Dec 2005 B2
7029470 Francischelli et al. Apr 2006 B2
7056294 Khairkhahan et al. Jun 2006 B2
7083566 Tornes et al. Aug 2006 B2
7112197 Hartley et al. Sep 2006 B2
7320695 Carroll Jan 2008 B2
7335197 Sage et al. Feb 2008 B2
7618430 Scheib Nov 2009 B2
7635353 Gurusamy et al. Dec 2009 B2
7651492 Wham Jan 2010 B2
7666203 Chanduszko et al. Feb 2010 B2
7678081 Whiting et al. Mar 2010 B2
7682360 Guerra Mar 2010 B2
7828796 Wong et al. Nov 2010 B2
7900928 Held et al. Mar 2011 B2
7963947 Kurth et al. Jun 2011 B2
8029470 Whiting et al. Oct 2011 B2
8114110 Bednarek et al. Feb 2012 B2
8157829 Chanduszko et al. Apr 2012 B2
8192425 Mirza et al. Jun 2012 B2
8257323 Joseph et al. Sep 2012 B2
8292910 Chanduszko et al. Oct 2012 B2
8317810 Stangenes et al. Nov 2012 B2
8337518 Nance et al. Dec 2012 B2
8388549 Paul et al. Mar 2013 B2
8500697 Kurth et al. Aug 2013 B2
8768433 Jenkins et al. Jul 2014 B2
8900193 Paul et al. Dec 2014 B2
8900214 Nance et al. Dec 2014 B2
8986264 Kimmel et al. Mar 2015 B2
8992556 Chanduszko et al. Mar 2015 B2
9162037 Belson et al. Oct 2015 B2
9326756 Stangenes et al. May 2016 B2
9357039 Conner et al. May 2016 B2
9358039 Kimmel et al. Jun 2016 B2
9533120 Kimmel et al. Jan 2017 B1
9585692 Kurth et al. Mar 2017 B2
9700351 Maisano et al. Jul 2017 B2
9717523 Feng et al. Aug 2017 B2
11339579 Stearns May 2022 B1
20010012934 Chandrasekaran et al. Aug 2001 A1
20010021867 Kordis et al. Sep 2001 A1
20020019644 Hastings et al. Feb 2002 A1
20020022781 McLntire et al. Feb 2002 A1
20020022836 Goble et al. Feb 2002 A1
20020035361 Houser et al. Mar 2002 A1
20020087153 Roschak et al. Jul 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020123749 Jain Sep 2002 A1
20020147485 Mamo et al. Oct 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020188302 Berg et al. Dec 2002 A1
20020198521 Maguire Dec 2002 A1
20030032929 McGuckin Feb 2003 A1
20030040742 Underwood et al. Feb 2003 A1
20030083560 Osypka May 2003 A1
20030144658 Schwartz et al. Jul 2003 A1
20030158480 Tornes et al. Aug 2003 A1
20030163153 Scheib Aug 2003 A1
20030225392 McMichael et al. Dec 2003 A1
20040015162 McGaffigan Jan 2004 A1
20040024396 Eggers Feb 2004 A1
20040030328 Eggers et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040073110 Stewart et al. Apr 2004 A1
20040073141 Hartley et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040077948 Violante et al. Apr 2004 A1
20040116851 Johansen et al. Jun 2004 A1
20040127963 Uchida et al. Jul 2004 A1
20040129352 Shiota Jul 2004 A1
20040133113 Krishnan Jul 2004 A1
20040133130 Ferry et al. Jul 2004 A1
20040143256 Bednarek Jul 2004 A1
20040147950 Mueller et al. Jul 2004 A1
20040181213 Gondo Sep 2004 A1
20040230188 Cioanta et al. Nov 2004 A1
20050004585 Hall et al. Jan 2005 A1
20050010208 Winston et al. Jan 2005 A1
20050049628 Schweikert et al. Mar 2005 A1
20050059966 McClurken et al. Mar 2005 A1
20050065507 Hartley et al. Mar 2005 A1
20050085806 Auge et al. Apr 2005 A1
20050096529 Cooper et al. May 2005 A1
20050101984 Chanduszko et al. May 2005 A1
20050119556 Gillies et al. Jun 2005 A1
20050137527 Kunin Jun 2005 A1
20050149012 Penny et al. Jul 2005 A1
20050203504 Wham et al. Sep 2005 A1
20050203507 Truckai et al. Sep 2005 A1
20050261607 Johansen et al. Nov 2005 A1
20050288631 Lewis et al. Dec 2005 A1
20060041253 Newton et al. Feb 2006 A1
20060074398 Whiting et al. Apr 2006 A1
20060079769 Whiting et al. Apr 2006 A1
20060079787 Whiting et al. Apr 2006 A1
20060079884 Manzo et al. Apr 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060089638 Carmel et al. Apr 2006 A1
20060106375 Werneth et al. May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060142756 Davies et al. Jun 2006 A1
20060189972 Grossman Aug 2006 A1
20060241586 Wilk Oct 2006 A1
20060247672 Vidlund et al. Nov 2006 A1
20060264927 Ryan Nov 2006 A1
20060276710 Krishnan Dec 2006 A1
20070005019 Okishige Jan 2007 A1
20070060879 Weitzner et al. Mar 2007 A1
20070066975 Wong et al. Mar 2007 A1
20070088355 Auth et al. Apr 2007 A9
20070118099 Trout, III May 2007 A1
20070123964 Davies et al. May 2007 A1
20070167775 Kochavi et al. Jul 2007 A1
20070173878 Heuser Jul 2007 A1
20070208256 Marilla Sep 2007 A1
20070225681 House Sep 2007 A1
20070270791 Wang et al. Nov 2007 A1
20080039865 Shaher et al. Feb 2008 A1
20080042360 Veikley Feb 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080097213 Carlson et al. Apr 2008 A1
20080108987 Bruszewski et al. May 2008 A1
20080125802 Carroll May 2008 A1
20080146918 Magnin et al. Jun 2008 A1
20080171934 Greenan et al. Jul 2008 A1
20080208121 Youssef et al. Aug 2008 A1
20080275439 Francischelli et al. Nov 2008 A1
20090105654 Kurth Apr 2009 A1
20090105742 Kurth Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090163850 Betts et al. Jun 2009 A1
20090177114 Chin et al. Jul 2009 A1
20090264977 Bruszewski et al. Oct 2009 A1
20100087789 Leeflang et al. Apr 2010 A1
20100125282 Machek et al. May 2010 A1
20100168684 Ryan Jul 2010 A1
20100179632 Bruszewski et al. Jul 2010 A1
20100191142 Paul et al. Jul 2010 A1
20100194047 Sauerwine Aug 2010 A1
20110022057 Eigler Jan 2011 A1
20110046619 Ducharme Feb 2011 A1
20110087261 Wittkampf et al. Apr 2011 A1
20110152716 Chudzik et al. Jun 2011 A1
20110160592 Mitchell Jun 2011 A1
20110190763 Urban et al. Aug 2011 A1
20120035590 Whiting Feb 2012 A1
20120232546 Mirza et al. Sep 2012 A1
20120265055 Melsheimer et al. Oct 2012 A1
20120330156 Brown et al. Dec 2012 A1
20130184551 Paganelli et al. Jul 2013 A1
20130184735 Fischell et al. Jul 2013 A1
20130282084 Mathur et al. Oct 2013 A1
20140188108 Goodine et al. Jul 2014 A1
20140206987 Urbanski et al. Jul 2014 A1
20140296769 Hyde et al. Oct 2014 A1
20140371676 Leeflang et al. Dec 2014 A1
20150173794 Kurth et al. Jun 2015 A1
20160022962 Beissel et al. Jan 2016 A1
20160089180 Entabi Mar 2016 A1
20160175009 Davies Jun 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20170189113 Urbanski et al. Jul 2017 A1
20170296781 Sapir et al. Oct 2017 A1
20180168687 Drake Jun 2018 A1
20190015644 Thomspon et al. Jan 2019 A1
20190021763 Zhou et al. Jan 2019 A1
20190247035 Gittard et al. Aug 2019 A1
Foreign Referenced Citations (4)
Number Date Country
2009112062 Sep 2009 WO
2013101632 Jul 2013 WO
2015019132 Feb 2015 WO
2020223230 Nov 2020 WO
Non-Patent Literature Citations (6)
Entry
Babaliaros V.C. et al. “Ermerging applications for transseptal left heart catheterization” (2008) J. American College of Cardiology, 51(22):2116-2122.
Earley M.J. “How to perform a transseptal puncture” (2009) Heart, 95:85-92. doi: 10.1146/hrt.2007.135939, Downloaded from heart.bmj.com on Jun. 16, 2009.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/030264, dated May 27, 2021, 29 pages.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/030264, dated Aug. 27, 2020, 14 pages.
PCT Demand and Amendments under Article 31 filed Feb. 24, 2021 in PCT application No. PCT/US2020/030264.
PCT International Search Report dated Apr. 25, 2019 in application No. PCT/US2018/063815.
Related Publications (1)
Number Date Country
20220080161 A1 Mar 2022 US
Provisional Applications (1)
Number Date Country
62594756 Dec 2017 US
Continuations (1)
Number Date Country
Parent 16209426 Dec 2018 US
Child 17537742 US